Demographics and RECIST best response summary of 16 evaluable patients with desmoid tumors treated on the DART immunotherapy protocol (nivolumab plus ipilimumab)
| Desmoid tumor (n=16) | N (%) |
| Age (years) (median (range)) | 37 (20, 82) |
| Sex | |
| Female | 12 (75.0) |
| Male | 4 (25.0) |
| Performance status | |
| 0 | 9 (56.3) |
| 1 | 7 (43.8) |
| Primary site | |
| Left medial masticator, pharyngeal mucosal and submandibular spaces | 1 (6.3) |
| Mesentery | 2 (12.5) |
| Rectum | 1 (6.3) |
| Skeleton | 1 (6.3) |
| Small intestine | 2 (12.5) |
| Soft tissue | 8 (50.0) |
| Thyroid | 1 (6.3) |
| Ethnicity | |
| Hispanic | 3 (18.8) |
| Not Hispanic | 13 (81.3) |
| Race | |
| White | 12 (75.0) |
| Black | 2 (12.5) |
| Unknown race | 2 (12.5) |
| Response | |
| Confirmed PR | 3 (18.8) |
| SD ≥6 months | 7 (43.8) |
| Clinical benefit* | 10 (62.5) |
| SD <6 months | 3 (18.8) |
| Not assessable† | 3 (18.8) |
*Clinical benefit=SD ≥ 6 months plus confirmed objective responses.
†One patient was not assessed (withdrew consent before the first scan), and the other two patients did not receive adequate scans.
DART, Dual Anti-CTLA-4 & Anti-PD-1 blockade in Rare Tumors; PR, partial response; SD, stable disease.